Investigational drug · Phase 3
Hetrombopag
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chemotherapy-Induced Thrombocytopenia, Immune Thrombocytopenia.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
56
Any phase or sponsor naming "Hetrombopag"
First trial start
2021
Mar 29, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Hetrombopag", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chemotherapy-Induced Thrombocytopenia
- Immune Thrombocytopenia
Approved drugs for the same conditions: Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Hetrombopag" as an intervention, largest first.
- An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AAStatus unknown
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT05333861 · 1,150 participants (planned) · Start May 1, 2022 · Primary completion May 1, 2026
Drug: hetrombopag · For: Primary Immune Thrombocytopenia; Aplastic Anemia
Sites: Wuhan, China
- Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) PatientPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03222843 · 424 participants · Start Jun 30, 2017 · Primary completion Nov 11, 2019
Drug: Hetrombopag Olamine; matching placebo · For: Idiopathic Thrombocytopenic Purpura
Sites: Wuhan, China; Chengdu, China; Tianjin, China
- A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor TherapyPivotal-lookingNot yet recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT07408648 · 244 participants (planned) · Start Apr 15, 2026 · Primary completion Apr 15, 2027
Drug: hetrombopag 7.5 mg orally once daily · For: Chemotherapy Induced Thrombocytopenia
- Hetrombopag or Placebo in Treatment-Naive Severe Aplastic AnemiaPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03825744 · 240 participants · Start Mar 5, 2019 · Primary completion Jul 3, 2024
Drug: Hetrombopag Olamine+Standard Therapy; Placebo+Standard Therapy · For: Severe Aplastic Anemia
Sites: Tianjin, China
- Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.Pivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05864014 · 213 participants · Start Apr 25, 2023 · Primary completion Mar 3, 2025
Drug: Hetrombopag; Hetrombopag plus Placebo and 1 more · For: Chemotherapy-Induced Thrombocytopenia
Sites: Haerbin, China
- A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients.Pivotal-lookingNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07334093 · 204 participants (planned) · Start Jan 31, 2026 · Primary completion Nov 15, 2027
Drug: rhTPO + hetrombopag; hetrombopag · For: Cancer Therapy-induced Thrombocytopenia (CTIT)
- TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Pivotal-lookingStatus unknown
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT05718856 · 166 participants (planned) · Start Feb 23, 2023 · Primary completion May 14, 2025
Drug: TPO-RAs; TPO-RAs combining anti-CD 20 monoclonal antibody · For: Primary Immune Thrombocytopenia (ITP)
Sites: Tianjin, China
- Extension Study of Hetrombopag in Severe Aplastic AnemiaPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04961710 · 157 participants · Start Sep 19, 2019 · Primary completion Nov 30, 2024
Drug: Hetrombopag Olamine; Placebo · For: Treatment-naive Severe Aplastic Anemia
Sites: Tianjin, China
- A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)Pivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07286032 · 150 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 2028
Drug: Hetrombopag Olamine; Hetrombopag Olamine; Hetrombopag Olamine Placebo · For: Patients With Chemotherapy-Induced Thrombocytopenia
Sites: Long Beach, California; Los Alamitos, California; Los Angeles, California · 51 sites in all
- A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer TherapyPivotal-lookingNot yet recruiting
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT07101627 · 149 participants (planned) · Start Aug 1, 2025 · Primary completion Apr 30, 2027
Drug: Hetrombopag Tablets · For: Lung Cancer
Sites: Nanjing, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Hetrombopag in China: expanding indications, comparative positioning, and risk management - a critical narrative review.
Chao F, Li R · Hematology 2026
- Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia.
Wang W, Wang H, Wan X, et al. · Platelets 2026
- Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia.
Wang D, Liu J, Tan A, et al. · Hematology 2026
- First-line hetrombopag combined with immunosuppressive therapy for paediatric severe aplastic anaemia: A prospective randomized controlled trial.
Fu L, Yang B, Wang R, et al. · Br J Haematol 2026
- Efficacy and safety of different TPO-RAs combined with cyclosporine in the treatment of NSAA.
Wang T, Wang B, Liu D, et al. · Ther Adv Hematol 2026
- Romiplostim for cancer treatment-induced thrombocytopenia in acute promyelocytic leukemia: a case report.
Yuan X, Guo Q, Zhang Z · Front Oncol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.